T Cell-Targeting Nanotherapies for Atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Medicine
• Nanotechnology

Background:

• Cardiovascular diseases, particularly atherosclerosis, are leading global causes of mortality.
• Current treatments primarily focus on lipid reduction, neglecting the inflammatory basis of atherosclerosis.
• T cell dysregulation, including increased T helper 1/17 and decreased T regulatory cells, drives atherosclerotic inflammation.

Purpose of the Study:

• To review the role of T cells in atherosclerosis pathogenesis.
• To examine existing nanotherapeutic strategies targeting T cells for atherosclerosis treatment.
• To provide perspectives on developing tailored nanoparticles for T cell-mediated atherosclerosis therapy.

Main Methods:

• Literature review of T cell involvement in atherosclerosis.
• Analysis of current nanomedicine approaches for modulating T cell responses.
• Exploration of nanoparticle functionalization for targeted delivery to immune cells within atherosclerotic lesions.

Main Results:

• T cell responses are critical in the inflammatory imbalance characteristic of atherosclerosis.
• Nanoparticle-mediated drug delivery presents a viable strategy for targeting T cells.
• Functionalized nanoparticles can deliver therapeutics specifically to immune cells in atherosclerotic lesions.

Conclusions:

• Targeting T cells offers a promising therapeutic avenue for atherosclerosis.
• Nanoparticle-based strategies hold potential for precise modulation of T cell differentiation and function.
• Further development of tailored nanoparticles is crucial for effective atherosclerosis nanotherapy.